Page 2 - Dementia Discovery Fund News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sudo raises $147M to advance 2 TYK2 inhibitor therapies to trials

Sudo raises $147M to advance 2 TYK2 inhibitor therapies to trials
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

Juergen eckhardtSudo biosciencesJonathan behrMatthias kleinzScott byrdDementia discovery fundSv health investors fundBayer agTranslational sciences investmentsEnavate sciencesRise fundSv health investorsFrazier life sciencesLife sciences innovationsSciences innovationsSanofi ventures

Exclusive: What Y Combinator partner Dalton Caldwell is looking for, as YC releases new Requests for Startups

For the first time in almost six years, Y Combinator is extensively outlining 20 new categories of startups they’re interested in seeing.

United statesSan diegoEteläuomen läiTel avivUnited kingdomChampagne ardenneFrance generalNew yorkCity ofMountain viewDiane greeneSanji biswasJared friedmanTommy tigheJoe abramsShoma nishikawa

Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round

The funding will advance two precision TYK2 inhibitors into the clinic for multiple sclerosis, psoriasis and other severe autoimmune and neurologic conditions.New investors include Dementia Discovery Fund, Leaps by Bayer, and UPMC Enterprises.CARMEL, Ind. (BUSINESS WIRE) #TYK2 Sudo Biosciences (“Sudo”), a biophar.

City ofUnited kingdomUnited statesMatthias kleinzSudo bioscienceJuergen eckhardtScott byrdSudo biosciencesJonathan behrEli lillyBill gatesOtsuka astexFrazier life sciencesBayer agPlayers associationQuest diagnostics

Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day

Bicycle Therapeutics (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, is today hosting a Research & Development (R&D) Day for investors and analysts in New York to provide clinical updates for BT8009, BT748

United kingdomNew yorkUnited statesKevin leeDrug administrationDementia discovery fundResearch development rd dayBicycle therapeuticsNobel prize winningSantiago arroyoChief development officerProject optimusInvestigational new drug enablingRadio conjugatesIonis therapeuticsBicycle toxin conjugate

Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day

Nectin-4 portfolio comprised of BT8009 and BT7480 represents potential opportunity to become leader in treating Nectin-4-driven cancers, starting with metastatic urothelial cancer Updated BT8009.

United kingdomNew yorkUnited statesKevin leeExchange commissionResearch development rd dayDrug administrationDementia discovery fundBicycle therapeuticsNobel prize winningSantiago arroyoChief development officerProject optimusInvestigational new drug enablingRadio conjugatesIonis therapeutics